177 related articles for article (PubMed ID: 35597058)
1. SMARCA4-deficient lung carcinoma is an aggressive tumor highly infiltrated by FOXP3+ cells and neutrophils.
Velut Y; Decroix E; Blons H; Alifano M; Leroy K; Petitprez F; Boni A; Garinet S; Biton J; Cremer I; Wislez M; Boudou-Rouquette P; Arrondeau J; Goldwasser F; Fournel L; Damotte D; Mansuet-Lupo A
Lung Cancer; 2022 Jul; 169():13-21. PubMed ID: 35597058
[TBL] [Abstract][Full Text] [Related]
2. SMARCA4/BRG1-Deficient Non-Small Cell Lung Carcinomas: A Case Series and Review of the Literature.
Nambirajan A; Singh V; Bhardwaj N; Mittal S; Kumar S; Jain D
Arch Pathol Lab Med; 2021 Jan; 145(1):90-98. PubMed ID: 33367658
[TBL] [Abstract][Full Text] [Related]
3. SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition.
Alessi JV; Ricciuti B; Spurr LF; Gupta H; Li YY; Glass C; Nishino M; Cherniack AD; Lindsay J; Sharma B; Felt KD; Rodig SJ; Cheng ML; Sholl LM; Awad MM
J Thorac Oncol; 2021 Jul; 16(7):1176-1187. PubMed ID: 33845210
[TBL] [Abstract][Full Text] [Related]
4. Cytomorphologic and immunophenotypical analysis of SMARCA4 (BRG1)-deficient non-small cell lung carcinoma.
Ogunbona OB; Lin X; Hornick JL; Lubin DJ; Wang Q; Reid MD; Schneider F; Li D; Shin DM; Shi Q
J Am Soc Cytopathol; 2022; 11(4):183-193. PubMed ID: 35491322
[TBL] [Abstract][Full Text] [Related]
5. Cytomorphologic features of SMARCA4-deficient non-small cell lung carcinoma and correlation with immunohistochemical and molecular features.
Sun T; Gilani SM; Podany P; Harigopal M; Zhong M; Wang H
Cancer Cytopathol; 2022 Aug; 130(8):620-629. PubMed ID: 35468657
[TBL] [Abstract][Full Text] [Related]
6. Cytology of SMARCA4-Deficient Thoracic Neoplasms: Comparative Analysis of SMARCA4-Deficient Non-Small Cell Lung Carcinomas and SMARCA4-Deficient Thoracic Sarcomas.
Nambirajan A; Dutta R; Malik PS; Bubendorf L; Jain D
Acta Cytol; 2021; 65(1):67-74. PubMed ID: 32854100
[TBL] [Abstract][Full Text] [Related]
7. SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1
Agaimy A; Fuchs F; Moskalev EA; Sirbu H; Hartmann A; Haller F
Virchows Arch; 2017 Nov; 471(5):599-609. PubMed ID: 28555282
[TBL] [Abstract][Full Text] [Related]
8. Thoracic SMARCA4-deficient tumors: a clinicopathological analysis of 52 cases with SMARCA4-deficient non-small cell lung cancer and 20 cases with thoracic SMARCA4-deficient undifferentiated tumor.
Zhou P; Fu Y; Tang Y; Jiang L; Wang W
PeerJ; 2024; 12():e16923. PubMed ID: 38374950
[TBL] [Abstract][Full Text] [Related]
9. SMARCA4 as a support for the differential diagnosis of poorly differentiated lung carcinomas.
Panozzi M; Alì G; Proietti A; Melfi F; Zirafa CC; Lucchi M; Fontanini G
Pathologica; 2023 Jun; 115(3):164-171. PubMed ID: 37387441
[TBL] [Abstract][Full Text] [Related]
10. Expanding the Immunophenotype Spectrum of SMARCA4-Deficient Non-Small Cell Lung Carcinomas: A Case Series with Neuroendocrine Markers Expression.
Mao R; Liu M; Shu X; Li W; Yan W; Li X
Int J Surg Pathol; 2022 May; 30(3):251-259. PubMed ID: 34633874
[No Abstract] [Full Text] [Related]
11. Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor.
Lin Y; Yu B; Sun H; Zhang H; Hu Z; Zhang Y; Wu Z; Sun S; Zhao X; Yu H; Wu X; Li Y; Wang J; Wang H
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8663-8671. PubMed ID: 37115272
[TBL] [Abstract][Full Text] [Related]
12. SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens.
Herpel E; Rieker RJ; Dienemann H; Muley T; Meister M; Hartmann A; Warth A; Agaimy A
Ann Diagn Pathol; 2017 Feb; 26():47-51. PubMed ID: 28038711
[TBL] [Abstract][Full Text] [Related]
13. Perspectives and Issues in the Assessment of
Armon S; Hofman P; Ilié M
Cells; 2021 Jul; 10(8):. PubMed ID: 34440689
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and prognostic analysis of SMARCA4-deficient non-small cell lung cancer.
Liang X; Gao X; Wang F; Li S; Zhou Y; Guo P; Meng Y; Lu T
Cancer Med; 2023 Jul; 12(13):14171-14182. PubMed ID: 37184108
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathological features of SMARCA4-deficient lung adenocarcinoma: a study of 42 cases].
Han J; Gao XZ; Xu Y; Liu EJ; Du Q; Chen K; Li SL
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):136-142. PubMed ID: 38281780
[No Abstract] [Full Text] [Related]
16. Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case report.
Naito T; Umemura S; Nakamura H; Zenke Y; Udagawa H; Kirita K; Matsumoto S; Yoh K; Niho S; Motoi N; Aokage K; Tsuboi M; Ishii G; Goto K
Thorac Cancer; 2019 May; 10(5):1285-1288. PubMed ID: 30972962
[TBL] [Abstract][Full Text] [Related]
17. SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer.
Bell EH; Chakraborty AR; Mo X; Liu Z; Shilo K; Kirste S; Stegmaier P; McNulty M; Karachaliou N; Rosell R; Bepler G; Carbone DP; Chakravarti A
Clin Cancer Res; 2016 May; 22(10):2396-404. PubMed ID: 26671993
[TBL] [Abstract][Full Text] [Related]
18. The clinicopathological features of BRG1-deficient non-small cell lung cancer and its response to immunotherapy: A single-center retrospective study.
Zhang J; Zhao R; Xu H; Dong L; Chen X
Ann Diagn Pathol; 2023 Dec; 67():152192. PubMed ID: 37639838
[TBL] [Abstract][Full Text] [Related]
19. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.
Oike T; Ogiwara H; Tominaga Y; Ito K; Ando O; Tsuta K; Mizukami T; Shimada Y; Isomura H; Komachi M; Furuta K; Watanabe S; Nakano T; Yokota J; Kohno T
Cancer Res; 2013 Sep; 73(17):5508-18. PubMed ID: 23872584
[TBL] [Abstract][Full Text] [Related]
20. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers.
Tagal V; Wei S; Zhang W; Brekken RA; Posner BA; Peyton M; Girard L; Hwang T; Wheeler DA; Minna JD; White MA; Gazdar AF; Roth MG
Nat Commun; 2017 Jan; 8():14098. PubMed ID: 28102363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
